MOTS-c: mouse data, human blood measurements, and no human trial

MOTS-c is sold as an "exercise mimetic" and a metabolic peptide. The science behind it is genuinely interesting and entirely preclinical. This is a short page because the human evidence is a single kind of measurement.

What it is

Mitochondria carry their own small genome. In the early 2000s researchers found that short open reading frames inside mitochondrial genes encode small peptides with signalling roles. MOTS-c, from the 12S rRNA gene, is one of them: 16 amino acids, released into the circulation, acting in part through the AMPK pathway and, under metabolic stress, moving into the cell nucleus to regulate genes.

The evidence

In mice. The 2015 Cell Metabolism paper (PubMed 25738459) reported that MOTS-c treatment prevented diet-induced obesity and insulin resistance. The 2021 Nature Communications paper (PubMed 33473109) reported that MOTS-c improved physical performance in young, middle-aged and old mice, and that starting intermittent treatment late in life increased physical capacity.

In humans. The same 2021 paper measured endogenous MOTS-c in human skeletal muscle and plasma and found that exercise raised it. That is the human data: a measurement of the body's own peptide, not an experiment in giving it. A 2023 review (PubMed 36761202) collects further observational associations between MOTS-c levels and metabolic disease.

Interventional human trials. We found none published. A MOTS-c analogue was taken into an early-phase trial by a biotechnology company several years ago; results were announced by press release and, as far as we can find, never published in a peer-reviewed journal. We do not grade press releases.

Regulatory status

FDA placed MOTS-c in Category 2 on September 29, 2023, and its page (content current as of April 22, 2026) now lists it as nominated but withdrawn. FDA's stated concerns are unusually blunt: "significant risk for immunogenicity for certain routes of administration," complexities with impurities and API characterisation, and "FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration."

The Pharmacy Compounding Advisory Committee discussed MOTS-c (free base and acetate) on July 23, 2026, with obesity and osteoporosis as the uses FDA evaluated. Whatever the committee's view, the 503A process ends with a final rule, and none exists. MOTS-c is not on the 503A bulks list and is not an ingredient of any approved drug.

Safety signals

None in humans, because there are no human exposure data. A peptide that signals through AMPK and translocates to the nucleus under stress is a plausible drug candidate and an equally plausible source of effects nobody has looked for. That is what a phase 1 trial is for, and no published one exists.

Grade: D + X

D because there is no interventional human study of any kind. X because FDA has published a specific safety concern. If your interest is metabolic, the peptides with actual human weight-loss trials are the GLP-1 agonists, which have tens of thousands of trial participants behind them and approved labels.